T1	intervention 0 10	Ribociclib
T2	total-participants 526 529	668
T6	control 842 864	placebo plus letrozole
T7	outcome-Measure 914 939	progression-free survival
T12	outcome 1498 1528	progression-free survival rate
T13	outcome 1483 1492	18 months
T14	iv-bin-percent 1533 1538	63.0%
T15	cv-bin-percent 1612 1617	42.2%
T16	outcome 1716 1737	overall response rate
T17	iv-bin-percent 1742 1747	52.7%
T18	cv-bin-percent 1752 1757	37.1%
T19	outcome 1790 1817	grade 3 or 4 adverse events
T20	outcome 1891 1902	neutropenia
T21	iv-bin-percent 1904 1909	59.3%
T22	cv-bin-percent 1938 1942	0.9%
T23	outcome 1969 1979	leukopenia
T24	iv-bin-percent 1981 1986	21.0%
T25	cv-bin-percent 1991 1995	0.6%
T26	outcome 2002 2052	rates of discontinuation because of adverse events
T27	iv-bin-percent 2058 2062	7.5%
T28	cv-bin-percent 2067 2071	2.1%
T3	outcome-Measure 971 987	overall survival
T4	outcome-Measure 989 1010	overall response rate
T5	outcome-Measure 1016 1022	safety
